Lilly, Alcon sign marketing deal for diabetic retinopathy drug candidate Arxxant

By E. Janene Geiss

Philadelphia, July 21 - Eli Lilly and Co. and Alcon, Inc. said Friday that they have signed a long-term agreement to co-promote ruboxistaurin mesylate or Arxxant in the United States and Puerto Rico.

Arxxant is an investigational oral drug for the treatment of moderate to severe nonproliferative diabetic retinopathy, a diabetic eye disease. It has the potential of becoming the first oral medication to treat diabetic retinopathy, officials said.

The co-promotion agreement is subject to Food and Drug Administration approval of Arxxant, which is under regulatory review, according to a company news release.

Under the agreement, Alcon said it will have primary responsibility for promotion to eye specialists, including retinal specialists and general ophthalmologists, while Lilly will have primary responsibility for promotion to endocrinologists and primary care physicians.

If Arxxant is approved by the FDA, Alcon said it will make milestone and marketing payments to Lilly and Alcon will be compensated based on product sales.

Alcon is a Fort Worth, Texas, eye care company.

Lilly is an Indianapolis pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.